Busulfan intravenous - SuperGen

Drug Profile

Busulfan intravenous - SuperGen

Alternative Names: Busulfan Partaject

Latest Information Update: 26 May 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SuperGen
  • Class Antineoplastics; Butylene glycols; Glycols; Mesylates; Myeloablative agonists; Small molecules
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bone marrow transplant rejection
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bone marrow transplant rejection; CNS cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 09 Dec 2002 Busulfan has received Orphan Drug Status for Bone marrow transplant rejection (Prevention, In paediatric patients)/Myeloablation in USA.
  • 01 Aug 2002 Phase-II clinical trials in CNS cancer in USA (Intravenous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top